TRML | Tourmaline Bio, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	14.91 - 15.77
52 Week Range	11.87 - 29.79
Beta	1.61
Implied Volatility	217.10%
IV Rank	44.33%
Day's Volume	260,628
Average Volume	309,613
Shares Outstanding	25,685,400
Market Cap	390,674,934
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-05-07

Valuation
Profitability
Growth
Health
P/E Ratio	-5.26
Forward P/E Ratio	N/A
EPS	-2.89
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	74
Country	USA
Website	TRML

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

*Chart delayed

Analyzing fundamentals for TRML we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see TRML Fundamentals page.

Watching at TRML technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on TRML Technicals page.